The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotech & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
Inception Date: 23/06/2005
Primary Benchmark: Dynamic Biotech&Genome Intellidex TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.58%
Management Expense Ratio: 0.59 %
|AMGN||Amgen Inc.||5.80 %|
|VRTX||Vertex Pharmaceuticals Incorporated||5.54 %|
|ILMN||Illumina Inc.||5.50 %|
|BIIB||Biogen Inc.||5.32 %|
|REGN||Regeneron Pharmaceuticals Inc.||5.06 %|
|NBIX||Neurocrine Biosciences Inc.||4.08 %|
|GHDX||Genomic Health Inc.||3.98 %|
|IONS||Ionis Pharmaceuticals Inc.||3.88 %|
|RGEN||Repligen Corporation||3.79 %|
|XLV||SPDR Select Sector Fund - Heal..||0.13 %||
|VHT||Vanguard Health Care||0.10 %||
|XBI||SPDR Series Trust S&P Biotech||0.35 %||
|IHI||iShares U.S. Medical Devices||0.43 %||
|FBT||First Trust Amex Biotech Index..||0.56 %||
|IYH||iShares U.S. Healthcare||0.43 %||
|FXH||First Trust Health Care AlphaD..||0.62 %||
|IXJ||iShares Global Healthcare||0.47 %||
|FHLC||Fidelity MSCI Health Care Inde..||0.08 %||
|IHF||iShares U.S. Health Care Provi..||0.43 %||
|Market Performance vs.
|Market Performance vs. Exchange (NYSE Arca)|
|Value||Sector Median||Percentile Rank||Grade||Market Median||Percentile Rank||Grade|
|Trailing 12 Months|
|Trailing 5 Years|
|Average Annual (5 Year Horizon)|
|Risk Return Profile|
|Volatility (Standard Deviation)||22.36%||21%||F||29%||F|
|Risk Adjusted Return||36.65%||21%||F||44%||F|
|Target Price Action||Rating Action||Analyst||Rating||Price||Date|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company has under performed its peers on annual average total returns in the past 5 years.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.